More effective & durable treatments for cancer and immunological diseases

We aim to develop medicines that can positively transform patient lives

Stamford Pharmaceuticals Inc clinical trials

News & Events

Who we are

We are a clinical stage oncology focused company developing novel gene therapies focused on dermatological and visceral cancers.

Learn More

Our Approach

Cancers are complex dynamic and adaptive diseases with the tumor micro-environment comprising many different cell types, matrix proteins and secreted molecules.

The interplay between these elements impacts the responsiveness to therapy and whether there is continued tumor survival and progression, even in the face of continued treatments. We believe that remodelling of the tumor microenvironment and taking a multi-pathway and multi-target approach offers an opportunity to significantly improving response rates and durability of response.

Learn More

Onco-Dermatology Pipeline addressing Multiple BCC Indications

Pipeline – Stage of Development

Product Indication Preclinical Phase 1 Phase 2 Phase 3 Status
SP-002: Phase 2A Multi-lesional Basal Cell Carcinoma
Study closed (Topline data in 2H, 2024)
SP-002: Phase 2B Locally Advanced BCC (combination regimen)
Study recruiting
SP-002: Phase 1/2A H&N Squamous Cell Carcinoma (combination regimen)
Commence in 1H, 20251
SP-105 Clinical Trial enabling studies
On-going CTN enabling studies
SP-500: Platform Preclinical evaluation

1 Subject to funding

about to commence
on-going studies

Our Disease Focus

Basal Cell Carcinoma

Locally Advanced Basal Cell Carcinoma and Basal Cell Nevus Syndrome are orphan Basal Cell Carcinoma indications.

Cutaneous Squamous Cell Carcinoma

Cutaneous squamous cell carcinoma (cSCC), is the second most common form of non-melanoma skin cancer (NMSC) comprising around 20% of all NMSC in the United States, with over 200,000 new cases each year.

Cutaneous Breast Cancer

Breast cancer is the most common cancer affecting women, with more than 1.2 million diagnosed cases worldwide annually. It is the second most common cancer after melanoma to metastasize to skin.